0001209191-18-057429.txt : 20181106 0001209191-18-057429.hdr.sgml : 20181106 20181106170047 ACCESSION NUMBER: 0001209191-18-057429 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181102 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRANDELL KEITH CENTRAL INDEX KEY: 0001219039 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 181163812 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH, SUITE 5 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH, SUITE 5 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-02 0 0001581280 Twist Bioscience Corp TWST 0001219039 CRANDELL KEITH 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 2018-11-02 4 C 0 1182645 A 1182645 I See footnotes Common Stock 2018-11-02 4 C 0 718275 A 1900920 I See footnotes Common Stock 2018-11-02 4 C 0 266776 A 2167696 I See footnotes Common Stock 2018-11-02 4 C 0 224726 A 2392422 I See footnotes Common Stock 2018-11-02 4 P 0 15000 14.00 A 2407422 I See footnotes Common Stock 2018-11-02 4 C 0 894146 A 894146 I See footnotes Common Stock 2018-11-02 4 P 0 60000 14.00 A 954146 I See footnotes Common Stock 0 D Series A Preferred Stock 2018-11-02 4 C 0 1182645 D Common Stock 1182645 0 I See footnotes Series B Preferred Stock 2018-11-02 4 C 0 718275 D Common Stock 718275 0 I See footnotes Series C Preferred Stock 2018-11-02 4 C 0 266776 D Common Stock 266776 0 I See footnotes Series D Preferred Stock 2018-11-02 4 C 0 224726 D Common Stock 224726 0 I See footnotes Series D Preferred Stock 2018-11-02 4 C 0 894146 D Common Stock 894146 0 I See footnotes Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Reflects shares purchased in the Issuer's initial public offering. The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The expiration date is not relevant to the conversion of these securities. /s/ William Solis, as Attorney-in-Fact 2018-11-06